Novanta Announces Financial Results for the Second Quarter 2026
Novanta Inc. (Nasdaq: NOVT) reported Q2 2026 GAAP revenue of $265.8 million, up 10.3% year over year, and GAAP net income of $12.5 million. Adjusted EBITDA rose 16.4% to $60.7 million and adjusted diluted EPS increased 17.1% to $0.89. The company also closed the Riverpoint Medical acquisition and raised Q3 and FY 2026 guidance.
How this was made
The 30-second read
Why it matters
The key trading driver is the combination of Q2 performance (revenue growth, margins, cash flow) and forward guidance ranges for Q3 and FY 2026 that incorporate Riverpoint Medical, plus management’s stated confidence in bookings and backlog.
Market read
This is a full earnings-and-guidance update with acquisition integration baked into the forecast, which typically drives immediate positioning changes.
What to watch
The release emphasizes non-GAAP metrics and provides no GAAP reconciliation for forward non-GAAP items; investors may focus on GAAP profitability durability and any acquisition-related purchase accounting effects.
Background
Novanta is a technology partner to medical and advanced technology equipment manufacturers and reported Q2 2026 results alongside updated guidance.
Ticker impact
Novanta reported Q2 2026 results and raised/updated Q3 and full-year 2026 guidance, explicitly incorporating the Riverpoint Medical acquisition.
Likely positive bias into the Aug 6 call, with volatility driven by whether investors buy the Riverpoint accretion and margin trajectory.
The article discloses multiple fresh, decision-relevant datapoints: Q2 beat on revenue growth and profitability metrics, operating cash flow surge, and explicit Q3 and FY 2026 GAAP and non-GAAP guidance ranges that now include Riverpoint.
Market effects
Signals strength in medical/advanced equipment supply chains via higher organic growth and consumables mix shift, potentially supportive for peers with similar end-markets.
Limited direct regional read-through; primarily company-specific guidance and acquisition execution.
Moderate, as the company assumes no significant FX changes and frames growth as portfolio and backlog driven rather than macro-dependent.
Counterpoint
Investors may discount the guidance if Riverpoint accretion assumptions or integration costs prove less favorable than management expects.
Key entities
- companyNovanta Inc.
Reported Q2 2026 financial results and updated Q3 and FY 2026 guidance, including Riverpoint Medical acquisition contribution.
- acquisitionRiverpoint Medical
Acquisition closed recently, described as roughly doubling recurring medical consumables and increasing medical end-market exposure.
- executiveMatthijs Glastra
Chair and CEO who commented on organic growth momentum and acquisition accretion expectations.
